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Abstract
OBJECTIVES—The long-term outcomes of patients with drug induced liver injury (DILI) are 
not well described. The aim of this study was to determine the frequency and severity of persistent 
liver biochemistry abnormalities in DILI patients followed over 2 years.
METHODS—Subjects with evidence of liver injury at 6 months after DILI onset were offered a 
month 12 and 24 study visit.
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RESULTS—Amongst the 99 patients with definite, probable, or very likely DILI and available 
laboratory data at 12 months after DILI onset, 74 (75%) had persistent liver injury (persisters) 
defined as a serum AST or ALT > 1.5 × upper limit of normal (ULN) or an alkaline phosphatase > 
ULN, while 25 (25%) had resolved liver injury (resolvers). On multivariate analysis, month 12 
persisters were significantly older (52.6 vs 43.7 years, p=0.01) and more likely to have a 
cholestatic lab profile at DILI onset (54% vs 20%, p < 0.01) than resolvers. The month 12 
persisters also had significantly poorer SF-36 Physical summary scores at DILI onset and 
throughout follow-up compared to the resolvers (p < 0.01). Amongst the 17 subjects with a liver 
biopsy obtained at a median of 387 days after DILI onset, 9 had chronic cholestasis, 3 had 
steatohepatitis, and 3 had chronic hepatitis.
CONCLUSION—75% of subjects with liver injury at 6 months after DILI onset have laboratory 
evidence of persistent liver injury during prolonged follow-up. Higher serum alkaline phosphatase 
levels at presentation and older patient age were independent predictors of persistent liver injury. 
Subjects with persistent liver injury at 12 months after DILI onset should be carefully monitored 
and assessed for liver disease progression.
Keywords
Hepatotoxicity; cholestasis; liver histology; ductular reaction
Introduction
Idiosyncratic drug induced liver injury (DILI) is a leading cause of acute liver failure (ALF) 
in western countries (1,2). We recently dmonstrated that approximately 60% of patients with 
bonafide DILI in the US required hospitalization and that 10% of patients died or underwent 
liver transplantation within 6 months of DILI onset (2,3). Furthermore, 19% had evidence of 
liver injury 6 months after DILI onset defined by an elevated liver biochemistry level, 
abnormal liver imaging or histopathology (2). Whether these patients will develop clinically 
significant liver disease or simply experience slowly resolving liver injury during prolonged 
follow-up is unknown. Prior studies have suggested that continued administration of the 
suspect drug and presentation with an acute cholestatic liver injury profile may result in a 
slower rate of laboratory improvement and an increased risk of developing chronic liver 
disease (4–6). However, the number of patients reported in these studies was limited and 
varying criteria were used to define chronic liver injury (4–8).
The aim of the current study is to describe the 2 year outcomes of consecutive adult DILI 
patients enrolled in the ongoing Drug Induced Liver Injury Network (DILIN) prospective 
study with evidence of ongoing liver injury 6 months after DILI onset. DILIN is a 
multicenter consortium sponsored by the National Institutes of Health that is conducting 
prospective studies focused on the etiology, risk factors, and natural history of DILI (8). For 
the current study, patients with persistent liver injury (persisters) were defined by a serum 
AST or ALT > 1.5 × upper limit of normal (ULN) or an alkaline phosphatase > ULN at 12 
months after DILI onset. Those not meeting these criteria were considered to have minimal 
to resolved liver injury (resolvers). Baseline and longitudinal parameters associated with 
persistent versus resolving liver injury at 12 months after DILI onset were identified. In 
addition to describing the evolution of laboratory parameters and liver histology, health 
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related quality of life parameters were compared in the month 12 persisters and resolvers 
through 2 years of follow-up.
METHODS
Patient population
991 patients were enrolled in the DILIN prospective registry study from September 2004 
through July 31, 2011. The research protocol was approved by the local institutional review 
boards and all participants provided written informed consent. The causal relationship 
between the liver injury episode and the implicated agent(s) were evaluated in a 
standardized fashion by the DILIN causality committee (8, 9). An overall DILIN causality 
score varying from 1 (Definite > 95% likelihood), 2 (Very Likely 75%–95% likelihood), 3 
(Probable 50%–74% likelihood), 4 (Possible 25%–49% likelihood) to 5 (unlikely < 25% 
likelihood) was assigned by consensus agreement of committee members (9). In cases with 
2 or more implicated drugs, an overall DILIN causality score was assigned and then an 
individual causality score was given for each suspect drug or herbal and dietary supplement 
(HDS). Of the 991 enrolled patients, 801 were adjudicated as definite, highly likely, or 
probable DILI. Of these 801 DILI patients, 143 were excluded from the analysis of early 
outcomes due to age < 18 (n=38), pre-existing chronic hepatitis B or C infection (n=28) or 
dropping out of the study before 6 month follow-up (n=77). (Figure 1) Of the remaining 660 
patients, there were 62 patients who either died or underwent liver transplantation within 6 
months of DILI onset. Thus, 598 adult DILIN patients had data available at baseline and 6 
months after DILI onset for analysis of chronic DILI risk factors.
Of these 598 patients, 113 had chronic DILI at least 6 months after DILI onset defined by 
one or more of the following criteria: elevated serum AST, ALT, alkaline phosphatase or 
total bilirubin level, histological evidence of liver injury, or radiological evidence of liver 
disease (i.e. ascites on imaging) (3,8). These 113 are the focus of this study, and per 
protocol, they were offered follow up through month 24 after DILI onset. Patients were 
categorized as either persisters or resolvers, based on the liver enzyme values at 12 months 
from DILI onset. Persisters were defined as serum AST or ALT > 1.5×upper limit of normal 
(ULN) or an alkaline phosphatase > ULN at 12 months from DILI onset. Resolvers did not 
meet these criteria and were considered to have minimal or no ongoing liver injury at 12 
months after DILI onset.
Clinical Data
A detailed medical and medication history was obtained at the baseline study visit and 
additional laboratory and radiological testing were performed to more fully characterize the 
DILI event and exclude competing etiologies of liver injury (2,8). Alcohol use was 
determined using the modified Skinner instrument. Heavy alcohol use in the 5 years prior to 
DILI onset was defined as a mean consumption of > 21 alcoholic beverages per week for 
men and >14 drinks per week for women. All enrolled patients were seen for a follow-up 
study visit at 6 months after initial enrollment. The subjects with ongoing liver injury at 6 
months after DILI onset returned for additional follow-up study visits at 12 and 24 months 
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after DILI onset. Severity of DILI injury was assessed on a 5 point scale used in the DILIN 
protocol with 1= asymptomatic to 5= Death/ liver transplant (8).
Assessment of symptoms
A 12 question likert scale was completed by subjects at baseline and month 6, 12, and 24 
study visits to assess for symptoms frequently reported in patients with liver disease 
including nausea, abdominal pain, fatigue, pruritus, pain over liver area, poor appetite, 
muscle aches, weakness, fevers and chills, rash, sadness, and overall feeling. The 10 point 
likert scale varied from 1 = Not at all to 10= worse ever.
Health related Quality of life (QOL)
The SF-36 (version 1.0) was completed at the baseline and months 6, 12, and 24 study visits 
(10). The questionnaire is comprised of 8 scales: physical functioning, social functioning, 
role limitations due to physical health, role limitations due to emotional problems, mental 
health, vitality, bodily pain, and general health perceptions. Responses to questions in each 
scale are combined to create a score ranging between 0 (low) to 100 (high). In addition, 
these individual scale scores can be combined to create separate physical and mental health 
summary scores. Population norms were obtained from the SF-36 scoring manual that 
consists of 2,474 individuals with 47% between the ages of 18–44 and 57% female. 
Population norms were available only for the physical and mental health composite scores.
Liver histopathology
Available liver biopsies were reviewed by a single expert liver histopathologist (DEK). All 
samples were scored for multiple histological features as well as an overall pattern of liver 
injury (11).
Statistics
The 113 patients with chronic DILI at 6 months after DILI onset were analyzed in this paper 
with available data through March 10th 2014 (2). The two time scales of time from DILI 
onset and time from baseline visit were used for different analyses due to the nature of data 
collection. For variables related to liver injury pattern over time (e.g aminotransferase 
values), the time from DILI onset was used. For variables related to data collected at the 
specific study visits (e.g. symptom likert scale and quality of life), the time scale from 
baseline visit was used. The classification of patients as persisters versus resolvers was 
computed based on available laboratory values within 12 months of the DILI onset.
Non-parametric Wilcoxon test was used for comparison of the two groups for continuous 
variables, and chi-square test for categorical variables. Stepwise multivariate logistic 
regression analyses were used to identify independent factors at DILI onset or baseline study 
visit selected by clinical judgment for predicting month 12 persistent versus resolved liver 
injury status. All model selection used an initial univariate analysis to screen potential 
candidates for multivariate modeling and only variables with < 50% missing data were used. 
Variables with a univariate p-value of 0.1 or less were considered including demographic 
variables (age, gender, race, weight, BMI) at baseline visit, signs and symptoms at DILI 
onset (except jaundice), medical histories, and various lab parameters at DILI onset. The 
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model results are reported as odds ratio (OR) with 95% confidence interval (CI). A c-
statistic was used to describe the fit of the final models.
SF-36 quality of life scores were compared between the groups by linear regression models 
with adjustment for age and gender. All p values reported are two-sided and a level of 0.05 
or less is considered statistically significant. All data were analyzed by SAS 9.2.
RESULTS
Patient population
Between September 2004 and August 2013, 113 of the 598 (18.8%) DILI patients had 
evidence of liver injury at 6 months after DILI onset. The manifestations of liver injury 
included serum AST, ALT, or alkaline phosphatase levels > baseline in 97 patients, liver 
function test 1.25 times of baseline on 2 occasions in 6, portal hypertension after 6 month 
from DILI onset in 8, radiological evidence of chronic liver injury in 23, histological 
evidence of chronic DILI in 6 and clinical evidence of chronic DILI in 36. Forty-three 
(38.1%) of the subjects met more than one criteria for chronic DILI. All of these patients 
were offered further study visits at 12 and 24 months after their baseline study visit wherein 
standardized laboratory, radiological and clinical assessments were undertaken. The 99 
patients with laboratory data obtained at 12 months from DILI onset form the basis of this 
report (Figure 1). Of note the age, gender, DILIN severity score, and DILIN causality score 
were not significantly different in the 14 patients with missing data at 12 months from DILI 
onset compared to the 99 included in this analysis (data not shown).
Persiters and Resolvers at 12 months after DILI onset
74 subjects had persistent laboratory evidence of liver injury at 12 months after DILI onset 
while 25 subjects were resolvers. Subjects with persistent liver injury had a similar BMI, 
gender, and racial distribution to those without persistent liver injury (Table 1). However, 
the month 12 persisters were significantly older (52.6 vs 43.7 years, p=0.01) and were more 
likely to have a history of heart disease (35.1% vs 4%, p < 0.01). Interestingly, those with 
persistent liver injury had a significantly higher initial and peak serum alkaline phosphatase 
level and a lower initial and peak serum ALT level. Not surprisingly, the proportion of 
subjects with cholestatic liver injury at presentation was higher in the persisters versus 
resolvers (54.1% vs 20%, p < 0.01). However, the initial and peak total bilirubin, albumin, 
and INR levels in the two groups were similar. The frequency of anti-nuclear antibodies 
(ANA) and smooth muscle antibodies were similar in the two groups. On multivariate 
analysis, subject age and higher serum alkaline phosphatase levels at DILI onset were 
independent predictors of persistent liver injury at 12 months after DILI onset (C-statistic = 
0.74 95% CI: 0.63: 0.85, See Supplemental Table 1).
The suspect drugs implicated in the month 12 persisters and resolvers were similar with 
antimicrobial antibiotics being the most commonly implicated agents in both groups 
(Supplemental Table 2). The mean causality scores were also similar in the two groups as 
were the DILIN severity scores (Table 1). In addition, the frequency of prednisone and 
ursodeoxycholic acid use during follow-up was similar in the two patient groups.
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Evolution of Liver biochemistries over time
The month 12 persisters had significantly higher serum alkaline phosphatase levels at DILI 
onset compared to those who resolved their liver injury at month 12. Although the serum 
alkaline phosphatase, total bilirubin and aminotransferase levels tended to improve in both 
groups over time, the persisters had significantly higher alkaline phosphatase levels at 
months 6, 12, and 24 compared to the resolvers (p < 0.01). In addition, although the serum 
AST and ALT levels were significantly lower at DILI onset in the persisters, they were 
subsequently higher than the resolvers at the month 6, 12, and 24 study visits (Table 2). The 
proportion of month 12 persisters and resolvers with serum ALT > 3 × ULN at DILI onset, 
month, 6, 12, and 24 were 73%, 27%, 27%, and 21% and 88%, 8%, 0%, and 5%, 
respectively.
SF-36 scores at baseline and follow-up study visits
The age and gender adjusted SF-36 scores of the two groups of patients are presented in 
Figure 2. At the baseline DILIN study visit, the persisters had significantly lower Physical 
Component Summary (PCS) scores (35 vs 42.4, p=0.003), Physical Function (PF) scores 
(51.9 vs 77 p=0.001), and General Health (GH) scores (56.2 vs 66.3, p=0.044) (Figure 2A). 
However, the Mental Health summary (MCS) scores and other subscale scores were similar. 
The PCS remained significantly lower in the month 12 persisters vs resolvers at month 6 and 
12 and were also lower at the month 24 study visit (Figure 2B). Furthermore, the Physical 
Function scores in the month 12 persisters were consistently lower compared to resolvers 
during follow-up as well (Figure 2C). These data indicate that the subjects with laboratory 
evidence of persistent liver injury 12 months after DILI onset have significantly poorer 
quality of life at initial enrollment that persists for 2 years compared to those with resolving 
liver injury.
Hepatitis symptoms at baseline and follow-up visits
11 clinical symptoms associated with acute hepatitis were recorded from all patients at the 
baseline, month 6, month 12, and 24 study visits (Supplemental Table 3). Subjects with 
laboratory evidence of persistent liver injury at 12 months had similar clinical symptoms at 
presentation to those who eventually resolved both at DILI onset and throughout follow-up.
Histopathologic evolution of DILI over time
A liver biopsy was not required for enrollment into the DILIN study and protocolized 
biopsies were not obtained during follow-up. Nonetheless, liver biopsy slides obtained by 
local physicians for clinical management purposes were available for review in 17 patients 
of whom 12 also had one or two biopsies during their acute DILI episode. For the 3 patients 
with 2 acute DILI biopsies, data from the second biopsy was utilized in Table 3. The mean 
age of these 17 subjects was 48.3 years and 70% were female. The median time from DILI 
onset to their initial liver biopsy was 22 days and 446 days to their additional biopsy done 
during follow-up. There were 14 individual agents implicated in these cases including 3 
patients with nitrofurantoin and 2 with azithromycin induced hepatotoxicity. The most 
common pattern of liver injury observed on follow-up biopsy was chronic cholestasis in 9 
patients (53%). Three patients each had either chronic hepatitis or steatohepatitis patterns. 
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Of note, seven patients had evidence of bile duct loss, including the only patient classified in 
blinded review as acute cholestasis (based on prominent zone 3 cholestasis and absence of 
inflammation or significant fibrosis). In the 12 patients with more than one biopsy, 8 
demonstrated fibrosis progression of at least one Ishak stage over a mean time interval of 
397 days. The only patient to show regression of fibrosis had DILI due to tamoxifen. This 
patient had three biopsies, demonstrating progression of steatohepatitis features and fibrosis 
between the first and second biopsies while she was receiving tamoxifen. However, 
following the discontinuation of tamoxifen, the third biopsy demonstrated regression of 
fibrosis as well as reduction in ballooning injury and steatosis. The 8 patients with fibrosis 
progression all had cholestatic liver injury and included all six of the patients with paired 
biopsies who showed bile duct loss.
An informative case of the histopathological evolution of persistent DILI is seen in Figure 3. 
A 51 year old Caucasian male presented with jaundice, pruritus and acholic stools after 
taking metoclopramide for 1 month for refractory gastroesophageal reflux disease. His 
initial ALT was 779 IU/l, alkaline phosphatase 859 IU/L, and total bilirubin 6.9 mg/dl and 
his bilirubin peaked 3 weeks later at 20.4 mg/dl. A liver biopsy obtained 89 days after DILI 
onset when his alkaline phosphatase was 1150 IU/l demonstrated mild portal infiltrates with 
periductal inflammation but no fibrosis. With persistent fatigue at approximately 16 months 
after DILI onset and an alkaline phosphatase of 659 IU/L and total bilirubin of 0.7 mg/dl, he 
underwent a 2nd liver biopsy that demonstrated marked chronic cholestatic changes with 
ductular reaction and ductopenia. The patient continued to have ongoing liver injury at his 
month 24 study visit with symptoms of fatigue and a serum ALT of 240 IU/L, alkaline 
phosphatase of 497 IU/L, and total bilirubin of 0.5 mg/dl.
Discussion
Prior studies have demonstrated that 5 to 10% of patients with idiosyncratic DILI will die or 
undergo liver transplantation within 6 months of DILI onset (1–3). In addition to 
characterizing early adverse outcomes, a primary aim of the DILIN prospective study is to 
better determine the long-term clinical outcomes in DILI patients with ongoing liver injury 
at 6 months or more after DILI onset (2,3). As a result, all eligible subjects had a 
standardized battery of liver biochemistries drawn and also had symptoms, medications, and 
interval medical history recorded at each follow-up study visit through 2 years. Early on, we 
noted that some of the patients completely normalized their labs during follow-up while 
others continued to have persistent laboratory abnormalities. Persistent liver injury was 
defined in this study as a patient with a serum AST or ALT > 1.5 × ULN or an elevated 
serum alkaline phosphatase level at 12 months after DILI onset (12,13). We feel that the 
objective, laboratory criteria we selected to define persistent liver injury at 12 months after 
DILI onset are reasonable since all of the patients had an episode of well-documented acute 
liver injury at enrollment (Table 1). Furthermore, serum AST and ALT levels were normal 
in 88 of the 99 patients included in this analysis who had labs available prior to starting the 
suspect medication. Using this definition, nearly 75% of the current cohort had laboratory 
evidence of ongoing liver injury at 12 months after DILI onset while the remaining 25% had 
resolved their liver injury as evidenced by normalization of laboratory results. Of note, the 
majority of subjects were not jaundiced at month 6 and this proportion remained low during 
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follow-up. However, the mean serum AST, ALT, and alk phos levels remained significantly 
higher in the month 12 persisters at month 24 compared to the resolvers (Table 2).
To determine if the month 12 persisters had more severe symptoms or functional impairment 
from their liver disease, we compared the self-reported symptom scores and SF-36 scores of 
the two patient groups at multiple time points. The clinical symptoms reported by both 
groups of patients were generally mild at their baseline study visit which took place a mean 
of 93 (range: 12 to 342) days after DILI onset in the persisters and 45 (range: 5 to 287) days 
after DILI onset in the resolvers. Furthermore, no significant differences in clinical 
symptoms were noted in the two groups during follow-up (Supplemental Table 3). However, 
clinically significant differences were noted in multiple SF-36 subscale and summary scores 
at the baseline study visit in the two groups of patients (Figure 2A). In particular, the 
physical function and role physical scores were markedly lower as was the PCS. The 
persistence of these differences during 2 years of follow-up suggest that subjects destined to 
have persistent DILI truly have a poorer quality of life and do not feel as well from DILI 
onset through 2 years of follow-up compared to those who will resolve their liver injury. It 
also suggests that our definition of persistent liver injury may have discerning value of 
clinical importance. Whether persisters go on to develop cirrhosis, portal hypertension, or 
symptoms of subclinical hepatic encephalopathy with more prolonged follow-up is an 
intriguing but unknown possibility worthy of further study (6).
Another aim of the current study was to identify baseline features associated with persistent 
liver injury that may be of use to clinicians in counseling future patients. Of note, there was 
no association between the type of suspect medication or duration of use with persistent 
DILI. However, the mean duration of suspect medication use in the 113 patients who formed 
the basis of this report was significantly longer than the 485 patients with self-limited DILI 
(2). Furthermore, gender, BMI, immunoallergic features (i.e. eosinophilia, rash, fever) and 
autoantibodies at DILI onset were also not associated with persistent liver injury. However, 
older patient age and higher serum alkaline phosphatase levels at presentation were both 
significant and independent risk factors for persistent DILI on multivariate analysis 
(Supplemental Table 1). The observed association of persistent liver injury with increasing 
patient age is not surprising. Studies of ALF patients have demonstrated that older subjects 
are more likely to die or experience greater morbidity presumably due to impaired hepatic 
regeneration (14). Older age is a strong determinant of developing chronic hepatitis C virus 
infection after initial exposure and older patients demonstrate greater evidence of hepatic 
inflammation and fibrosis progression during follow-up (15, 16). Older donor livers also do 
not fare as well in living and deceased donor liver transplantation and aging promotes the 
development of hepatic inflammation and liver cell injury in animal models of hepatic 
steatosis (17–19). These data cumulatively suggest that older individuals are at greater risk 
of developing severe and potentially progressive liver injury following an acute DILI 
episode compared to younger individuals.
The observation that subjects with cholestatic liver injury at DILI onset are at greater risk of 
having persistent liver injury during prolonged follow-up is perhaps one of the most 
important findings from our study. Some drugs associated with cholestatic liver injury early 
on can lead to severe prolonged cholestasis and even ductopenia during follow-up in a 
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minority of afflicted patients (20–22). In particular, some patients with severe acute 
cholestatic drug reactions may go on to develop protracted liver disease with repeated 
hospitalizations and even development of cirrhosis (6). Furthermore, subjects with a 
cholestatic DILI episode in one study were more likely to develop chronic liver injury and a 
small proportion of these patients also developed progressive liver fibrosis (5). However, the 
mechanism(s) behind this association remains unclear. In primary biliary cirrhosis, there is 
evidence that the Canals of Hering along with the small bile ducts, are targets of an immune-
mediated attack (23, 24). This disrupts the normal relationship of hepatocytes to bile ducts, 
stimulating a ductular reaction that can lead to subsequent hepatic fibrosis (25). Among our 
eight cases with fibrosis progression, six showed duct loss and four showed ductular 
reaction, while none of the four cases without fibrosis progression had either duct loss or 
ductular reaction (Table 3). Therefore, we speculate that the mechanism(s) of fibrosis 
involved in our chronic cholestatic DILI cases may be similar to those involved in other 
immune-mediated chronic cholestatic liver diseases but additional studies of a larger group 
of consecutive DILI patients are needed. The patients with clinically driven follow-up liver 
biopsies available for review in our cohort provided us a unique opportunity to explore the 
pathological evolution of chronic liver injury from DILI. Although only a few patients had 
follow-up biopsies, in those that did, the biopsies mainly showed chronic injury patterns 
with varying severity of hepatic fibrosis and just over half showed chronic cholestasis. This 
histological pattern of injury is in keeping with the persistent cholestatic laboratory injury 
profile and is unlikely to be the result of pre-existing liver disease. In patients with a 
baseline and a follow-up biopsy, some fibrosis progression was seen in two-thirds of cases, 
even though the time between biopsies was relatively short. All six patients who showed 
duct loss on follow-up had fibrosis progression and may be at risk for the development of a 
biliary cirrhosis. The only patient that showed clear regression of fibrosis had steatohepatitis 
due to tamoxifen.
There are several limitations of our study. Firstly, only a minority of patients had liver 
biopsy performed during follow-up and these were for clinical indications which may have 
led to selection bias. In addition, the biopsies were not obtained at a uniform time after DILI 
onset. Furthermore, we cannot completely exclude the possibility that some of the persisters 
may have had hepatic steatosis prior to taking the suspect drug. However, only 16% of the 
patients with labs available prior to starting the suspect medication had abnormal liver 
biochemistries. In addition, the mean BMI and frequency of diabetes mellitus and other 
components of the metabolic syndrome were not more prevalent in the persisters (Table 1). 
Furthermore, the predominance of cholestatic enzyme injury at DILI onset and at 12 months 
in the persisters suggests more than just mild fatty liver was detected by our enzyme criteria. 
Lastly, a multitude of suspect drugs were implicated in these 99 patients precluding us from 
linking the likelihood of persistent liver injury developing to a specific drug or class of 
drugs. Nevertheless, these data represent the largest group of patients with bona fide DILI 
(i.e. high causality assessment scores) who have been prospectively monitored for long-term 
clinical outcomes. In addition, clinically and statistically significant impairments in health 
related quality of life were noted in month 12 persisters compared to the resolvers 
throughout the study providing clinical relevance to our definition of persistent liver injury 
at 12 months after DILI onset.
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In conclusion, 75% of subjects with liver injury at 6 months after DILI onset have persistent 
laboratory evidence of liver injury during further follow-up. Older patients and those that 
present with a higher serum alkaline phosphatase level are more likely to have persistent 
laboratory abnormalities during follow-up and also report a significantly poorer quality of 
life through month 24. Therefore, patients with persistent laboratory abnormalities at 12 
months after DILI onset should be carefully monitored for clinical and histological 
progression of liver disease. Our natural history data also suggest that selected patients may 
benefit from a medical therapy aimed at reducing ductular damage and fibrosis progression 
but additional studies are needed.
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What is current knowledge
- Idiosyncratic drug induced liver injury (DILI) is an important cause of 
clinically significant liver injury that is associated with a 10% 6-month 
mortality.
- Little is known about the long-term outcomes of DILI patients including the 
evolution of laboratory abnormalities, liver histology, and HRQOL.
- The NIH Drug Induced Liver Injury Network (DILIN) is conducting an 
ongoing prospective study of 2 year outcomes in patients who have evidence 
of liver injury 6 months after DILI onset.
What is new here
- Amongst 99 patients with probable DILI, 75% had laboratory evidence of 
persistent liver injury at 12 months after DILI onset with clinically significant 
reductions in various HRQOL domains throughout follow-up compared to 
resolvers.
- Older patient age and a cholestatic lab profile at DILI onset were associated 
with a greater likelihood of persistent liver injury during follow-up.
- Analysis of available serial liver biopsy specimens demonstrated evidence of 
progressive liver injury with chronic cholestasis and progressive hepatic 
fibrosis in over 2/3rd of the patients.
- Persistent liver biochemical abnormalities are common in DILI patients with 
injury at 6 months after DILI onset; these patients require careful monitoring 
for liver disease progression
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Figure 1. Overview of Study population
Amongst the 598 patients enrolled in DILIN between 9/04 and 7/11, 113 patients met 
protocol defined criteria for ongoing liver injury at 6 months after DILI onset. Amongst 
those patients, the 99 subjects with laboratory data available at month 12 after DILI onset 
were categorized as Persisters (n=75) if they had abnormal liver biochemistries or resolvers 
(n=24).
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Figure 2. Quality of life scores
A- Mean adjusted SF-36 summary and subscale scores at the Baseline study visit. The mean 
PCS, PF, and General health (GH) scores were significantly lower in the month 12 persisters 
versus resolvers. 2B). The PCS scores improved in both groups of patients but significant 
differences remained in the month 6, month 12, and month 24 PCS scores between the 
subjects with persistent and resolved liver injury 2C). The Physical function (PF) scores of 
the month 12 persisters remained significantly lower than the resolvers at the baseline, 
month 6, month 12, and month 24 study visits. PF= Physical function BP= Bodily pain RP= 
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role physical GH= general health VT= vitality SF= social functioning RE= Role emotional 
MH= mental health PCS= Physical summary score, MCS= Mental health summary score
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Figure 3. Chronic liver injury due to metaclopramide
A. In the initial biopsy, taken 89 days after DILI onset, there is a mild portal infiltrate with 
periductal inflammation and duct injury (arrowhead). No fibrosis was present.
(Magnification 400 ×) B. Visible bile (arrows) was present in the parenchyma. 
(Magnification 600 ×) C. Enzyme abnormalities persisted and a second biopsy, taken 492 
days after DILI onset, showed chronic cholestatic changes with marked ductular reaction 
and ductopenia. The portal areas were greatly expanded by fibrosis. (Magnification 200 ×).
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Table 1








Age (yrs) 52.6 ± 14.0 43.7 ± 17.3 0.01
Female (%) 69% 68% 1.00
Race (%) 1.00
  Caucasian 74% 76%
  Black 18% 20%
  Asian 5% 4%
  Others 3% 0%
Hispanic (%) 5% 8% 0.64
BMI (kg/m2) 27.5 ± 6.4 28.1 ± 9.2 0.77
Self-reported drug allergies (%) 49% 28% 0.10
Medical History
  Diabetes mellitus (%) 34% 24% 0.46
  Heart disease (%) 35% 4% < 0.01
Any alcohol prior to DILI onset (%) a 40% 68% 0.02
Amongst drinkers b
  Heavy alcohol use (%) 17% 23% 0.70
Implicated agents
Duration of agent use (days) 54 (1, 2343) 32 (1, 2120) 0.70
  Single drug (%) 50% 56% 0.23
  Single HDS (%) 4% 12%
    Multiple drug(s) /or HDS (%) 46% 32%
Primary implicated agent class 0.88
  Antimicrobial (%) 38% 36% 1.00
  Antineoplastic (%) 13% 12% 1.00
  Cardiovascular (%) 15% 8% 0.51
  HDS (%) 8% 24% 0.07
  Endocrine (%)
7% 0% 0.33
7% 0% 0.33
  Gastrointestinal (%) 3% 8% 0.26
  Analgesic (%) 3% 8% 0.26
  CNS (%) 3% 0% 1.00
  Immunolomodulatory (%) 4% 4% 1.00





















Liver biochemistries at DILI onset
Serum AST (U/L) 266 (29, 2125) 367 (45, 2077) 0.07
Serum ALT (U/L) 275 (14, 2733) 553 (121, 2412) 0.01
Alk P (U/L) 394 (41, 1730) 219 (74, 783) <.01
Total bilirubin (mg/dl)
5.2 (0.2, 29.7) 7.2 (0.2, 36.2) 0.24
1.2 (0.9, 3.5) 1.1 (0.9, 3.2) 0.48
INR
Albumin (g/dL) 3.5 (1.7, 4.6) 3.7 (2.3, 4.4) 0.29
MELD score 16.5 (6.0, 40.0) 18.0 (6.0, 40.0) 0.65
R-value 1.8 (0.1, 70.2) 8.0 (1.0, 27.8) <.01
Pattern of Injury
  Cholestatic (%) 54% 20% <.01
  Mixed (%) 18% 20%
  Hepatocellular (%) 28% 60%
Causality score (%) 0.49
Definite 15% 16%
Very likely 53% 64%
Probable 32% 20%
  Corticosteroid use (%) 47% 44% 1.00
  Ursodeoxycholic acid use (%) 26% 12% 0.18
Peak liver biochemistries within 6 months of DILI onset
Serum AST (U/L) 354 (57, 3229) 462 (116, 2343) 0.33
Serum ALT (U/L) 428 (62, 3742) 630 (133, 2412) 0.05
Alk P (U/L) 599 (65, 2865) 246 (90, 1016) <.01
Total bilirubin (mg/dl) 13.8 (0.5, 54.8) 10.8 (0.4, 38.2) 0.66
INR 1.2 (0.9, 13.1) 1.2 (0.9, 3.2) 0.22
Lowest Albumin (g/dL 2.7 (0.6, 4.9) 3.3 (1.3, 4.2) 0.04
Data reported as mean ± standard deviation or median (range)
^
Month 12 persisters vs resolvers
a
% with any alcohol use prior to DILI onset
b
Determined from Skinner Survey in 5 years prior to DILI onset.
Heavy alcohol use defined as > 21 drinks/ week in men and > 14 drinks/week in women
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Table 2
Evolution of liver biochemistries in the Month 12 persisters vs resolvers over time





At DILI Onset (n) (74) (25)
Serum AST (U/L) 266 (29, 2125) 367 (45, 2077) 0.07
Serum ALT (U/L) 275 (14, 2733) 553 (121, 2412) 0.01
Alk P (U/L) 394 (41, 1730) 219 (74, 783) <.01
Total bilirubin (mg/dl) 5.2 (0.2, 29.7) 7.2 (0.2, 36.2) 0.24
T bilirubin > 2.5 mg/dl (%) 71% 79% 0.6
At Month 6 (n) (70) (24)
Serum AST (U/L) 73 (27, 1258) 47 (18, 140) <.01
Serum ALT (U/L) 78 (13, 1627) 66 (13, 216) 0.09
Alk P (U/L) 275 (53, 1487) 116 (32, 277) <.01
Total bilirubin (mg/dl) 0.9 (0.1, 16.3) 0.6 (0.4, 2.4) 0.01
T Bilirubin > 2.5 mg/dl (%) 13% 0% 0.11
At Month 12 (n) (74) (25)
Serum AST (U/L) 67 (29, 2335) 29 (15, 50) <.01
Serum ALT (U/L) 79 (16, 1223) 40 (13, 73) <.01
Alk P (U/L) 245 (58, 1333) 92 (35, 151) <.01
Total bilirubin (mg/dl) 0.9 (0.3, 33.4) 0.6 (0.1, 2.4) 0.03
T bilirubin > 2.5 mg/dl (%) 7% 0% 0.33
At Month 24 (n) (66) (19)*
Serum AST (U/L) 50 (17, 410) 30 (16, 558) <.01
Serum ALT (U/L) 50 (19, 407) 32 (9, 1211) <.01
Alk phos 157 (54, 1389) 82 (47, 228) <.01
Total bilirubin (mg/dl) 0.8 (0.3, 3.8) 0.6 (0.2, 3.7) 0.28
T Bilirubin > 2.5 mg/dl (%) 3% 5% 0.54
Data reported as median (range)
*
A single patient with normal liver biochemistries at 12 months after DILI onset subsequently developed acute cholestatic liver injury at month 24 
attributed to symptomatic gallstones.
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